Seer (SEER) Q1 2026 earnings review
Revenue Collapses Amid Funding Headwinds and Emerging Competition
Seer experienced a severe reversing trend in Q1 2026, with revenue plunging 34% YoY to $2.8 million. Management cited a depressed academic funding environment and, notably, new 'competitive activity' as primary culprits. The volume shock crushed profitability, driving gross margins down to 35% from 49% a year ago. While operating expenses were cut by 20% to manage cash burn, the company's maintained FY26 guidance of $16M-$18M now implies a massive and highly risky acceleration required in the back half of the year. The addition of the 10,000-sample PRECISE-SG100K study is a bright spot, but near-term financial execution is faltering.
🐂 Bull Case
Seer ended the quarter with $220 million in cash and investments. With Q1 free cash flow burn at $15.7 million, the company has years of runway to navigate the current academic funding trough without dilution.
The PRECISE-SG100K partnership in Singapore secures deep proteomics profiling on 10,000 samples, validating the platform's ability to handle population-scale multi-ancestry cohorts.
🐻 Bear Case
After stabilizing at ~$4.1M-$4.2M per quarter throughout 2025, revenue abruptly fell to $2.8M. The admission of 'competitive activity' suggests Seer may be losing its monopoly grip on unbiased proteomics.
Gross margins plummeted to 35%. If this is driven by competitive pricing concessions rather than just under-absorbed fixed costs, the long-term profitability model of the Proteograph system is at risk.
⚖️ Verdict: 🔴
Bearish. The abrupt 34% drop in revenue breaks the previous narrative of stable, early-adopter growth. Adding 'competition' to the list of excuses (alongside NIH funding) introduces severe structural risk to their growth story.
Key Themes
Admission of Competitive Pressure
For the first time, management explicitly cited 'competitive activity in the space we have pioneered' as a core reason for the 34% revenue decline. In 2025, blame was placed squarely on NIH budgets and macro uncertainty. If competitors are successfully encroaching on Seer's unbiased proteomics niche, sales cycles will further elongate and pricing power will erode.
Gross Margin Compression
Gross profit reversed sharply, with margins dropping from 49% in 25Q1 to just 35% in 26Q1. This 14-point compression is severe. Given the low absolute revenue base, this is likely due to the negative operating leverage of fixed manufacturing costs against lower unit volumes, though competitive discounting cannot be ruled out.
Population-Scale Cohort Wins
Despite near-term financial weakness, Seer continues to secure foundational large-scale studies. The newly announced collaboration with Precision Health Research, Singapore (PRECISE-SG100K) to process 10,000 samples represents a massive consumable pull-through opportunity and validates the technology in multi-ancestry applications.
Aggressive Expense Management
Management successfully decelerated cash burn by reducing operating expenses 20% YoY to $18.2 million. This was primarily driven by cuts in employee compensation and a drop in stock-based compensation (from $4.5M to $2.1M). As a result, the net loss actually narrowed YoY ($16.8M vs $19.9M) despite the top-line collapse.
Accelerating Third-Party Validation
Independent publications detailing Proteograph's utility doubled year-over-year to 84. Management views this 'activation energy' as critical for converting academic researchers from targeted legacy proteomics methods to Seer's unbiased discovery platform. A U.S. Patent and Trademark Office Final Written Decision also reinforced Seer's IP moat against infringement.
Other KPIs
Decelerating sharply from prior quarters (down 27% vs $2.89M in 25Q1). This segment, consisting of Proteograph instruments and consumable kits, is the core of the business model. The severe drop indicates stalled instrument placements and weak consumable pull-through.
Reversing trend, cut by more than half compared to $1.2M in 25Q1. Service revenue primarily consists of Seer Technology Access Center (STAC) projects. In 2025, STAC was touted as a primary funnel for instrument conversions; a collapse here signals weakness in the top-of-funnel sales pipeline.
Stable compared to historical quarters. The balance sheet remains heavily fortified with $220 million in cash, cash equivalents, and investments. The company also repurchased ~1.5 million shares, taking advantage of the depressed valuation.
Guidance
Stable trajectory sequentially, but implies a massive H2 acceleration. Given Q1 delivered only $2.8 million, Seer needs to average ~$4.7 million over the next three quarters just to hit the $17 million midpoint. This implies an expectation of a sharp recovery, likely reliant on unannounced large-scale studies or a sudden unthawing of NIH budgets.
Key Questions
Competitive Landscape Shift
You explicitly noted 'competitive activity' impacting Q1 revenue. Can you identify which specific alternative technologies or companies are lengthening your sales cycles or taking market share?
Bridge to FY26 Guidance
With only $2.8 million in Q1 revenue, achieving the $16-$18 million full-year guidance requires an aggressive ramp. Is this guidance back-end loaded due to specific, contracted cohort studies (like the Singapore agreement) moving into the consumable phase, or are you assuming a macro recovery in academic budgets?
Gross Margin Mechanics
Gross margins compressed by 14 points year-over-year to 35%. How much of this decline is structural due to competitive pricing concessions, versus temporary under-absorption of fixed manufacturing costs on a lower revenue base?
STAC Pipeline Weakness
Service revenue dropped significantly year-over-year. Given STAC was previously highlighted as a key funnel that drove half of instrument placements, does this quarter's drop indicate a thinning pipeline for future instrument sales?